中文摘要：

目的通过对宫颈癌细胞系HeLa细胞中Bcrpl’表型细胞的侵袭和成瘤能力的研究，探讨Bcrpl成为宫颈癌干细胞表面标志物的可能性。方法根据实验中所用HeLa细胞表型的不同分为两组，即Bcrpl’组和Bcrpl一组，利用穿膜小室——boydon小室体外侵袭实验检测两组细胞的侵袭能力；将不同细胞密度梯度（1×10^4、1×10^5、1×10^6个m1）的Bcrpl’及Bcrpl一组细胞分别接种于6—8周龄非糖尿病一严重免疫缺陷（NOD／SCID）小鼠体内，比较两组小鼠的体内成瘤情况，包括成瘤时间、成瘤率、肿瘤体积及肿瘤质量。结果体外侵袭实验显示，Bcrpl’组穿膜细胞数为（99±14）个，侵袭深度为（366±52）μm，明显高于Bcrpl一组的（57±13）个和（301±54）μm，两组分别比较，差异均有统计学意义（P〈0．05）。体内成瘤实验显示，接种细胞密度为1×10^4个／ml时，Bcrpl’组小鼠体内即可形成移植瘤；接种细胞密度为1×10^5和1x10^6个／ml时，Bcrpl^＋组和Bcrpl一组小鼠体内均可形成移植瘤；与Bcrpl一组小鼠比较，Bcrpl’组小鼠接种相应细胞密度的成瘤时间早、成瘤率高、肿瘤体积和肿瘤质量大，两组分别比较，差异均有统计学意义（P〈0．05）。结论Bcrpl’表型的HeLa细胞与Bcrpl一表型相比，具有较强的成瘤及侵袭能力，具备肿瘤干细胞的部分特征，其中可能富集了宫颈癌干细胞。

英文摘要：

Objective To make sure whether or not Bcrpl is the marker of cervical cancer stem cells or not by studying the invasive ability and formation of tumors of Berpl ＋ phenotype HeLa cells. Methods The tumor cell migration and invasion assay were used by boyden chamber to identify the invasive ability of Bcrpl ＋ phenotype HeLa cells. The formation of tumors in vivo experiments were completed, in which the two groups of cells with different concentrations were inoculated in non obese diabetes-severe combined immunodefieieney disease （NOD/SCID） mice （1 x 10^4 ,1 x l0^5, 1x10^6/ml） , and the differences of time, rate and volume in the formation of tumors between two groups were observed. Results （1） In the invasion assay, the amount of cells that invaded through the artificial basement membrane in Bcrpl ＋ group were 99±14, which was significantly greater than those in Bcrpl - group （57±13, P 〈0. 05） ;the length of the Bcrpl group was （366±52） p.m, which was significantly greater than the Bcrpl - group （301±54） p,m （P 〈0.05）. （2） Following transplantation of 1 x 104 cells, only the Berpl ＋ cells formed tumors in NOD/SCID mice. When 1 x 10^5 or 1 x 10^6 cells were transplanted, the tumor incidence and the tumor mass were greater in the Bcrpl ＋ groups than those in the Berpl - groups （P 〈 0. 05）. Conclusion Bcrpl ^＋HeLa cell have the greater capacity of invasive and the tumorigenicity, which may contain cancer stem cells.